Ticagrelor to Improve Venous Graft Patency

Saphenous vein graft patency is one of CABG’s “Achilles heals”, especially after the ARTS trial came out showing bilateral internal mammary artery grafting was not superior to simple internal mammary artery grafting. 

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

Antiaggregation more potent than aspirin might prolong venous graft patency in cases when the available techniques will fail to improve poor outcomes.   

Previous studies tend to confirm the idea that a more potent antiaggregation therapy could prolong patency. However, reality seems to have debunked this attractive hypothesis. 

This double-blind placebo-controlled randomized study showed that adding ticagrelor does not reduce graft occlusion rate at one-year followup. These outcomes contradict prior study outcomes. 

There is no conclusive evidence to support routine indication of ticagrelor in patients undergoing CABG. 


Read also: Same Contrast Dose, Different Risk of Kidney Injury, Depending on Procedure.


Ticagrelor does have antithrombotic effect and probably pleiotropic in patients undergoing CABG in the context of acute coronary syndrome, but this benefit is associated to the clinical syndrome, rather than graft patency.  

Guidelines still recommend administering ticagrelor after acute coronary syndrome with revascularization, regardless the technique. 

499 patients mean age 67.9±8.3 with myocardial revascularization indication were randomized. One third of the cohort received revascularization in the context of acute coronary syndrome. 


Read also: Do We Need to See a Cardiologist before a Carotid Endarterectomy?


Occlusion rate of venous graft with ticagrelor was 10.5% vs 9.1% in the placebo arm (both arms received low doses of aspirin). 

This difference was not significative.

Conclusion

In this randomized placebo-controlled study, adding ticagrelor to aspirin did not improve saphenous vein graft patency vs. standard aspirin monotherapy.

Título original: The Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.

Referencia: Willemsen LM et al. Circulation. 2020 Aug 31. Online ahead of print. doi: 10.1161/CIRCULATIONAHA.120.050749.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...